Viral Vectors (VV) based ATMP Therapies have been in commercial manufacturing for over 10 years. The science of VV-based ATMPs continues to evolve rapidly. This has had a marked impact to the design of ATMP manufacturing facilities. This presentation reviews three case studies which demonstrate the evolution of facilities designed and built in the past 5 years. The presentation will showcase how facility design innovation has evolved as the therapies and their manufacturing has become more complicated.